What impact do side effects have on elderly chronic myeloid leukemia (CML) patients?
Misconceptions about the use of biosimilars
FLT3 inhibitors - their role in AML
Developments in CML over the past 30 years and where we are today
New subtypes of acute lymphoblastic leukemia (ALL) – potential treatment identification by genomics